Semiautomatic Aerosol Propellant Filler
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Testing and Research (OTR), is seeking a Semiautomatic Aerosol Propellant Filler for pMDI Two-Stage Formulation. This Request for Quotation (RFQ), issued under Full and Open Competition, includes purchase, delivery, installation, validation support, training, and warranty services. The equipment will support FDA research in advanced pharmaceutical manufacturing and inhalation drug delivery systems. Quotations are due by June 22, 2026, at 11:00 AM Eastern Time.
Scope of Work
The requirement is for a complete semiautomatic aerosol propellant filling system, including accessories. Key components include a pressure filler system (on-column design, 0.5-20 mL adjustable dosing cylinder, 316L stainless steel contact parts), a crimper assembly (on-column design, large crimping head for 20 mm valves), a crimp height measuring gauge, and a propellant pump assembly (up to 15 liters/minute, compatible with HFA, LPG, DME propellants). Contractor responsibilities cover packaging, transportation, delivery, installation, operational testing, Factory Acceptance Testing (FAT) documentation, validation support, user training, manuals, and a minimum one-year warranty.
Contract & Timeline
- Contract Type: Firm-Fixed-Price (FFP) purchase order.
- Term: Date of award through one year after award.
- Place of Performance: U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD 20993.
- Set-Aside: Full and Open Competition (Not a Small Business Set-Aside).
- Delivery/Installation: Within 90 calendar days after award.
- Questions Due: June 15, 2026, at 9:00 AM Eastern Time.
- Quotations Due: June 22, 2026, at 11:00 AM Eastern Time.
- Published: June 10, 2026.
Evaluation
Award will be based on Lowest Price Technically Acceptable (LPTA). Evaluation factors include Technical Acceptability (Pass/Fail), Past Performance (Acceptable/Neutral/Unacceptable), and Price. Offerors must hold pricing firm for 120 calendar days after quotation closing.
Submission Requirements
- Submit quotations electronically to Michele.Jackson@fda.hhs.gov.
- Include in the Subject Line:
[Company Name] – 75F40126Q00231/CDER-2026-133243 Quote. - Required attachments include a Pricing Schedule, Past Performance Reference Form, Brand Name or Equal Compliance Matrix (if proposing an equal product), and Buy American Act Compliance Certification.
- Offerors must be registered in the System for Award Management (SAM).
Contact
Primary point of contact is Michele Jackson at Michele.Jackson@fda.hhs.gov.